This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


  • 00
  • 00
  • 00
  • 00
Delivered as a Hybrid Event from December 12 - 16, 2021
Live In-Person Experience Delivered December 12 - 16 2021Marriott Marquis San Diego

Gregory Adams, PhD
Chief Scientific Officer at Elucida Oncology


Dr. Adams is Chief Scientific Officer (CSO) of Elucida Oncology, company developing novel targeted nanoparticle drug conjugates for the treatment of cancer. Prior to joining Elucida he was CSO at Sesen Bio/Eleven Biotherapeutics and Chief Development Officer at Viventia Bio.  Before moving to biotech, Dr. Adams was the Director of Biological Research and Therapeutics and previously co-led the Developmental Therapeutics Program at the Fox Chase Cancer Center, an NCI designated comprehensive cancer center in Philadelphia.
Dr. Adams is an immunologist with over 30 years of experience in developing antibody-based agents for the treatment and detection of cancer. He received a Ph.D. in Immunology from the University of California at Davis in 1991. He joined Fox Chase Cancer Center in Philadelphia where he led a laboratory focused on developing antibodies and antibody-drug conjugates for the treatment of breast, ovarian and renal cancer.
Dr. Adams serves on the Editorial Boards of Cancer Immunology Research, MAbs and Cancer Biotherapy & Radiopharmaceuticals.  He has served on the Scientific Advisory Boards of a number of biotechnology companies including Endo Pharmaceuticals, Symphogen, Avipep, Viventia Bio, AvidBiologics, Xerion, Fabrus, Integral Molecular and YM Biosciences.

Agenda Sessions

  • Co-Chairs’ Remarks

  • ELU001, A Targeted Topoisomerase-1-C’Dot Conjugate for the Treatment of Folate Receptor Alpha Overexpressing Cancers